Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Microbiol ; 58(Pt 7): 951-958, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19498204

ABSTRACT

Streptococcus agalactiae is a contagious, mastitis-causing pathogen that is highly adapted to survive in the bovine mammary gland. This study used a BALB/c mouse model of Streptococcus agalactiae mastitis to evaluate leukocyte populations in regional lymph nodes and cytokine expression in the mammary gland involved in the immune response against Streptococcus agalactiae. It was found that the bacteria replicated efficiently in the mammary gland, peaking after 24 h and increasing by 100-fold. Dissemination of bacteria to systemic organs was observed 6 h after infection. At the same time, a massive infiltration of polymorphonuclear cells and an increase in the inflammatory cytokines interleukin (IL)-1beta, IL-6 and tumour necrosis factor-alpha were detected in mammary glands, indicating an early inflammatory response. A decrease in the levels of inflammatory cytokines in mammary glands was observed 72 h after infection, accompanied by an increase in the levels of IL-12 and IL-10, which were related to a gradual decrease in bacterial load. An increase in the number of macrophages and B220(+) lymphocytes and similar increases in both CD4(+) and CD8(+) T cells in regional lymph nodes were observed, being most pronounced 5 days after infection. Moreover, increased levels of anti-Streptococcus agalactiae antibodies in the mammary gland were observed 10 days after infection. Overall, these data suggest that the host exhibits both innate and acquired immune responses in response to Streptococcus agalactiae mastitis.


Subject(s)
Mammary Glands, Animal/cytology , Mammary Glands, Animal/immunology , Mastitis/immunology , Streptococcal Infections/immunology , Streptococcus agalactiae , Animals , Antibodies, Bacterial , Cattle , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Female , Gene Expression Regulation/physiology , Leukocytes/metabolism , Mammary Glands, Animal/microbiology , Mammary Glands, Animal/pathology , Mastitis/microbiology , Mastitis/pathology , Mice , Mice, Inbred BALB C , Streptococcal Infections/microbiology , Time
2.
J Infect Dis ; 199(1): 116-23, 2009 Jan 01.
Article in English | MEDLINE | ID: mdl-18956975

ABSTRACT

Dental caries is among the more prevalent chronic human infections for which an effective human vaccine has not yet been achieved. Enolase from Streptococcus sobrinus has been identified as an immunomodulatory protein. In the present study, we used S. sobrinus recombinant enolase (rEnolase) as a target antigen and assessed its therapeutic effect in a rat model of dental caries. Wistar rats that were fed a cariogenic solid diet on day 18 after birth were orally infected with S. sobrinus on day 19 after birth and for 5 consecutive days thereafter. Five days after infection and, again, 3 weeks later, rEnolase plus alum adjuvant was delivered into the oral cavity of the rats. A sham-immunized group of rats was contemporarily treated with adjuvant alone. In the rEnolase-immunized rats, increased levels of salivary IgA and IgG antibodies specific for this recombinant protein were detected. A significant decrease in sulcal, proximal enamel, and dentin caries scores was observed in these animals, compared with sham-immunized control animals. No detectable histopathologic alterations were observed in all immunized animals. Furthermore, the antibodies produced against bacterial enolase did not react with human enolase. Overall, these results indicate that rEnolase could be a promising and safe candidate for testing in trials of vaccines against dental caries in humans.


Subject(s)
Bacterial Vaccines/therapeutic use , Dental Caries/prevention & control , Phosphopyruvate Hydratase/therapeutic use , Streptococcal Infections/prevention & control , Streptococcus sobrinus/immunology , Vaccines, Synthetic/therapeutic use , Administration, Oral , Animals , Bacterial Vaccines/administration & dosage , Dental Caries/microbiology , Female , Immunization Schedule , Male , Mouth/microbiology , Rats , Streptococcus sobrinus/enzymology , Streptococcus sobrinus/isolation & purification , Vaccines, Synthetic/administration & dosage
3.
Can J Microbiol ; 54(11): 899-905, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18997846

ABSTRACT

Streptococcus agalactiae is a common pathogen that causes bovine mastitis. The aims of this study were to evaluate the antibody response against S. agalactiae extracellular proteins in the whey and serum of naturally infected bovines and to identify possible immunodominant extracellular antigens. IgG1 antibodies against S. agalactiae extracellular proteins were elevated in the whey and serum of naturally infected bovines. In the whey, the levels of IgG1 specific for S. agalactiae extracellular proteins were similar in infected and noninfected milk quarters from the same cow, and the production of antibodies specific for S. agalactiae extracellular proteins was induced only by infection with this bacterium. The immunoreactivity of extracellular proteins with bovine whey was clearly different in infected versus control animals. Group B protective surface protein and 5'-nucleotidase family protein were 2 major immunoreactive proteins that were detected only in the whey of infected cows, suggesting that these proteins may be important in the pathogenesis of S. agalactiae-induced mastitis. This information could be used to diagnose S. agalactiae infection. In addition, these antigens may be useful as carrier proteins for serotype-specific polysaccharides in conjugate vaccines.


Subject(s)
5'-Nucleotidase/immunology , Antigens, Bacterial/immunology , Antigens, Surface/immunology , Bacterial Proteins/immunology , Mastitis, Bovine/immunology , Streptococcal Infections/veterinary , Streptococcus agalactiae/immunology , Animals , Antibodies, Bacterial/analysis , Antibodies, Bacterial/blood , Cattle , Female , Immunoglobulin G/analysis , Immunoglobulin G/blood , Mastitis, Bovine/microbiology , Streptococcal Infections/immunology , Streptococcal Infections/microbiology , Streptococcus agalactiae/genetics , Streptococcus agalactiae/isolation & purification
4.
J Immunol ; 178(3): 1379-87, 2007 Feb 01.
Article in English | MEDLINE | ID: mdl-17237385

ABSTRACT

Certain extracellular proteins produced by several pathogenic microorganisms interfere with the host immune system facilitating microbial colonization and were thus designated virulence-associated immunomodulatory proteins. In this study, a protein with B lymphocyte stimulatory activity was isolated from culture supernatants of Streptococcus agalactiae strain NEM316. This protein, with an apparent molecular mass of 45 kDa, was identified as GAPDH by N-terminal amino acid sequencing. The gapC gene was cloned and expressed in Escherichia coli for the production of a recombinant histidyl-tagged protein. The recombinant GAPDH (rGAPDH), purified in an enzymatically active form, induced in vitro an up-regulation of CD69 expression on B cells from normal and BCR transgenic mice. In addition, rGAPDH induced an increase in the numbers of total, but not of rGAPDH-specific, splenic Ig-secreting cells in C57BL/6 mice treated i.p. with this protein. These in vitro- and in vivo-elicited B cell responses suggest that the B cell stimulatory effect of rGAPDH is independent of BCR specificity. A S. agalactiae strain overexpressing GAPDH showed increased virulence as compared with the wild-type strain in C57BL/6 mice. This virulence was markedly reduced in IL-10-deficient and anti-rGAPDH antiserum-treated mice. These results suggest that IL-10 production, which was detected at higher concentrations in the serum of rGAPDH-treated mice, is important in determining the successfulness of the host colonization by S. agalactiae and they highlight the direct role of GAPDH in this process. Taken together, our data demonstrate that S. agalactiae GAPDH is a virulence-associated immunomodulatory protein.


Subject(s)
Bacterial Proteins/physiology , Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)/physiology , Glyceraldehyde-3-Phosphate Dehydrogenases/physiology , Interleukin-10/biosynthesis , Streptococcus agalactiae/enzymology , Streptococcus agalactiae/pathogenicity , Animals , Antigens, Bacterial/genetics , B-Lymphocytes , Bacterial Proteins/genetics , Immunologic Factors , Interleukin-10/analysis , Lymphocyte Activation , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Streptococcus agalactiae/immunology , Virulence , Virulence Factors
5.
Cell Microbiol ; 6(1): 79-88, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14678332

ABSTRACT

A strategy of Streptococcus sobrinus, a major agent of dental caries, to survive and colonize the host consists of the production of a protein that suppresses the specific antibody responses. We have cloned the gene coding for a protein with immunosuppressive activity. It contains an open reading frame of 1302 base pairs encoding a polypeptide with 434 amino acid residues and a molecular mass of 46910 Da. The gene product is homologous to enolases from several organisms. The polypeptide was expressed in Escherichia coli as a hexahistidine-tagged protein and purified in a fluoride-sensitive enzymatically active form. Pretreatment of mice with the S. sobrinus recombinant enolase suppresses a primary immune response against T-cell dependent antigens. This immunosuppressive effect is specific to the antigen used in the immunization, as it is not observed when the immune response against other antigens is analysed. Furthermore, the S. sobrinus recombinant enolase stimulates an early production of interleukin-10, an anti-inflammatory cytokine, and not the pro-inflammatory cytokine IFN-gamma. These observations indicate that enolase acts in the suppression of the specific host immune response against S. sobrinus infection.


Subject(s)
Immune Tolerance , Phosphopyruvate Hydratase/genetics , Phosphopyruvate Hydratase/immunology , Streptococcus sobrinus/enzymology , Amino Acid Sequence , Animals , Antigens, Bacterial/administration & dosage , Antigens, Bacterial/immunology , Bacterial Proteins/genetics , Bacterial Proteins/isolation & purification , Bacterial Proteins/metabolism , Base Sequence , DNA, Bacterial/chemistry , DNA, Bacterial/isolation & purification , Immunization , Interferon-gamma/biosynthesis , Interleukin-10/biosynthesis , Mice , Molecular Sequence Data , Molecular Weight , Phosphopyruvate Hydratase/chemistry , Phosphopyruvate Hydratase/metabolism , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Sequence Alignment , Sequence Analysis, DNA , Streptococcus sobrinus/immunology , Streptococcus sobrinus/pathogenicity
6.
Microbiology (Reading) ; 149(Pt 2): 333-339, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12624195

ABSTRACT

Here, it is shown that immunoneutralization of p43, a virulence-associated immunomodulatory protein secreted by Candida albicans, is responsible for immunoprotection against candidiasis after spontaneous healing of mice inoculated with 10(6) C. albicans blastoconidia. p43 is produced by the pathogenic Candida blastoconidia, and neither immunoprotection nor immunoneutralization can be elicited by priming the mice with attenuated or heat-killed C. albicans blastoconidia. The immunoprotection against systemic candidiasis was positively correlated with (i). serum levels of antibodies against p43 and (ii). a high ratio between antibodies against p43 and antibodies against C. albicans structural antigens. Immunoprotection against candidiasis can be induced in mice primed with heat-killed C. albicans, after treatment of the animals with anti-p43 antibodies. The data described here provide a biological explanation for active immunoprotection achieved after spontaneous healing of infectious diseases, namely in candidiasis.


Subject(s)
Antibodies, Fungal/immunology , Candida albicans/pathogenicity , Candidiasis/prevention & control , Fungal Proteins/immunology , Animals , Antibodies, Fungal/blood , Antibodies, Fungal/therapeutic use , Antigens, Fungal/immunology , Candida albicans/growth & development , Candida albicans/immunology , Candidiasis/immunology , Candidiasis/microbiology , Fungal Vaccines/administration & dosage , Fungal Vaccines/immunology , Immunization , Immunization, Passive , Male , Mice , Mice, Inbred BALB C , Neutralization Tests , Secondary Prevention , Virulence
SELECTION OF CITATIONS
SEARCH DETAIL